Proton Pump Inhibitors (PPIs) Explained: Uses, Safety, and Long-Term Risks

What Are Proton Pump Inhibitors?

Proton pump inhibitors (PPIs) are a class of medications that suppress stomach acid production by irreversibly blocking the hydrogen-potassium ATPase enzyme (the "proton pump") in the stomach's parietal cells. They are among the most widely prescribed drugs in the world, used for gastroesophageal reflux disease (GERD), peptic ulcer disease, H. pylori eradication, and prevention of NSAID-induced ulcers.

Common PPIs include omeprazole (Prilosec), pantoprazole (Protonix), esomeprazole (Nexium), lansoprazole (Prevacid), rabeprazole (Aciphex), and dexlansoprazole (Dexilant). Omeprazole and lansoprazole are available over the counter; the others require a prescription.

How PPIs Work

The stomach produces acid through a proton pump (H+/K+-ATPase) located in parietal cells of the gastric lining. This pump exchanges hydrogen ions (H+) for potassium ions (K+), secreting acid into the stomach lumen. PPIs are prodrugs — they are absorbed in the small intestine, enter the bloodstream, and are selectively taken up by parietal cells, where they are converted to their active form (a sulfenamide) in the acidic environment of the secretory canaliculus. The active form covalently binds to and irreversibly inhibits the proton pump.

Because the inhibition is irreversible, acid suppression lasts 24–48 hours — longer than the drug's plasma half-life (~1–2 hours). New acid secretion requires synthesis of new proton pumps, which takes 18–24 hours. This is why PPIs are taken once daily, typically 30–60 minutes before the first meal (to ensure maximum pump activation at the time of drug absorption).

What Are PPIs Used For?

Comparing the PPIs

Long-Term Risks of PPI Use

PPIs are safe for short-term use. However, long-term use (beyond 8–12 weeks) is associated with several risks that have been identified in observational studies. It is important to note that most of these associations are modest, and causality is not always established — patients on long-term PPIs often have more comorbidities than those not on PPIs.

Vitamin B12 Deficiency

Stomach acid is required to release vitamin B12 from food proteins. Long-term acid suppression can impair B12 absorption, leading to deficiency over years. A 2013 JAMA study found that PPI use for >2 years was associated with a 65% increased risk of B12 deficiency. Patients on long-term PPIs should have B12 levels checked periodically and may need supplementation.

Magnesium Deficiency (Hypomagnesemia)

Long-term PPI use can cause severe hypomagnesemia (low magnesium), which can cause muscle cramps, tremors, seizures, and cardiac arrhythmias. The FDA issued a safety communication about this risk in 2011. Magnesium levels should be checked before starting long-term PPI therapy and periodically thereafter.

Bone Fractures

Multiple observational studies have found an association between long-term PPI use and increased risk of hip, wrist, and spine fractures — particularly in older patients. The proposed mechanism is reduced calcium absorption due to acid suppression. The FDA added a fracture warning to PPI labels in 2010. The absolute risk increase is modest, but patients on long-term PPIs should ensure adequate calcium and vitamin D intake.

Clostridium difficile Infection

Stomach acid provides a barrier against ingested pathogens. PPI use is associated with a 1.5–2× increased risk of C. difficile infection, which causes severe diarrhea and colitis. This risk is particularly relevant in hospitalized patients and those on antibiotics.

Community-Acquired Pneumonia

Several studies have found an association between PPI use and increased risk of pneumonia, possibly due to bacterial overgrowth in the less acidic stomach. The absolute risk increase is small.

Chronic Kidney Disease

A 2016 JAMA Internal Medicine study found that PPI use was associated with a 20–50% increased risk of chronic kidney disease. The mechanism is unclear and causality has not been established. This association should not prevent appropriate PPI use but supports the principle of using the lowest effective dose for the shortest necessary duration.

PPI Overuse: A Major Problem

Studies consistently show that 40–70% of patients on PPIs do not have a clear indication for the drug. PPIs are often started in the hospital for stress ulcer prophylaxis and never discontinued. They are also frequently prescribed for non-specific GI symptoms without confirming a diagnosis of GERD or peptic ulcer disease. Inappropriate long-term PPI use exposes patients to unnecessary risks and costs.

How to Stop PPIs Safely

Abrupt discontinuation of long-term PPIs can cause "rebound acid hypersecretion" — a temporary increase in acid production above baseline that causes heartburn and reflux symptoms. This can last 2–4 weeks and often leads patients to restart the PPI. To minimize rebound:

1. Taper gradually (e.g., reduce from daily to every other day over 2–4 weeks)
2. Switch to an H2 blocker (famotidine, ranitidine) during the taper
3. Use antacids as needed for breakthrough symptoms
4. Implement lifestyle modifications (elevate head of bed, avoid trigger foods, lose weight if overweight)

References

1. Lam JR, et al. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310(22):2435-2442.
2. Lazarus B, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238-246.
3. Freedberg DE, et al. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the AGA. Gastroenterology. 2017;152(4):706-715.